According to Arbutus Biopharma 's latest financial reports the company's current revenue (TTM) is $18.14 M. In 2022 the company made a revenue of $39.01 M an increase over the years 2021 revenue that were of $10.98 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $18.14 M | -53.51% |
2022 | $39.01 M | 255.11% |
2021 | $10.98 M | 58.92% |
2020 | $6.91 M | 15.02% |
2019 | $6.01 M | 1.11% |
2018 | $5.94 M | -44.44% |
2017 | $10.7 M | 617.64% |
2016 | $1.49 M | -94.01% |
2015 | $24.87 M | 66.34% |
2014 | $14.95 M | -3.39% |
2013 | $15.47 M | 10.45% |
2012 | $14.01 M | -17.04% |
2011 | $16.89 M | -20.82% |
2010 | $21.33 M | 63.03% |
2009 | $13.08 M | 33.71% |
2008 | $9.78 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
NRC Health
NRC | $0.14 B | 719.03% | ๐บ๐ธ USA |